ABSTRACT -Liposomes are lipid based vesicular systems that offer novel platform for versatile drug delivery to target cell. Liposomes were first reported by Bangham and his co-workers in 1964 (1). Since then, liposomes have undergone extensive research with the prime aim to optimize encapsulation, stability, circulation time and target specific drug delivery. Manipulation of a liposome's lipid bilayer and surface decoration with selective ligands has transformed conventional liposomes into adaptable and multifunctional liposomes. Development of liposomes with target specificity provide the prospect of safe and effective therapy for challenging clinical applications. Bioresponsive liposomes offer the opportunity to release payload in response to tissue specific microenvironment. Incorporation of novel natural and synthetic materials has extended their application from stable formulations to controlled release targeted drug delivery systems. Integration and optimization of multiple features into one system revolutionized research in the field of cancer, gene therapy, immunotherapy and infectious diseases. After 50 years since the first publication, this review is aimed to highlight next generation of liposomes, their preparation methods and progress in clinical applications.
INTRODUCTION
Liposomes are lipid based vesicular systems in which a well-defined aqueous core is contained within a lipid bilayer. In May 1964, Alec D. Bangham and his colleagues reported spontaneously forming lipid vesicles and named them as "smectic mesophases" (1). These vesicle were named "Bangasomes" after the name of Bangham, the father of liposomes. In 1968, Weissmann coined a more descriptive term "liposomes", an analogy to the term lysosomes (2). Liposomes were initially used as membrane models in biological studies. However, the cell-like structure of liposomes persuaded scientist to investigate liposomes as a tool to smuggle potent drug molecules into human body. In 1971, first report was published on the liposomal encapsulation of a therapeutic agent (3). Liposomes can load hydrophilic drugs in aqueous core and increase penetration through lipophilic physiological membranes while lipophilic drugs are contained inside the lipid bilayer and increase their solubility in the aqueous body fluids (4). Liposome demonstrates better protection from external degradation caused by enzymes (5) and because they are prepared from natural materials or their synthetic derivatives, liposomes are biocompatible and biodegradable (6).
Conventional liposomes have some drawbacks. They are complex to produce, have less inherent stability and therefore, cannot be stored for a long time. Liposomes show rapid uptake by the reticuloendothelial system thus decreasing their circulation half-life. Leakage of loaded drugs from liposomes resulted in less drug loading efficiency. New materials and techniques employed in liposomal research may be toxic and non-biocompatible (7). Recently, it has been reported that repeated low dose injections may lead to accelerated blood clearance of liposome (8) . _________________________________________ To overcome these drawbacks, liposomes have undergone extensive research on surface modification, size optimization and understanding the disposition mechanism.
The next generation of liposomes is characterized by high mechanical stability, ability to induce or inhibit the immune system, longer circulation times, improved loading efficiency, enhanced penetration and target specificity. Accordingly, liposomes have emerged as promising carriers for sensitive drugs and macro molecules. Indeed, progress in pharmacology has introduced a number of potent therapeutic agents that require drug carriers that are selective and bio-responsive. This challenge to control drug release has been a milestone in the development of next generation liposomes. The improvements in liposomes include long circulating or stealth liposomes that have been prepared by decorating liposome surface with hydrophilic polymers such as polyethylene glycol which reduces liposomes uptake by the reticuloendothelial system (9) and toxicity of encapsulated drugs (10). Stealth liposomes have long circulation life and constitute an integral part of controlled release multifunctional liposomes. On the other hand, PEGylation or stealthing strongly inhibits cellular uptake of liposomes which limits its application in macrophage and tumor targeting. The problem has been addressed by the development of cleavable PEG systems that can detach PEG in response to target tissue microenvironment (11). A negative charged DNA can bind a positively charged lipid forming cationic liposomes with reduced size and increased circulation time (12). Targeted specificity is achieved by anchoring targeting ligands which bind to the desired receptors (13). The number of lamellae or crosslinking of lipid controls the drug release rate from liposomes (14). Different drugs can be loaded in different lamella that enables sequential release of drugs and simplifies the treatment regimen (15). Liposomal microarrays have been employed for the detection of proteins and peptides in different body fluids (16). Chimeric liposomes have been prepared by the combination of phospholipids with low quantities of other biomaterials to control physiochemical and structural properties of liposomes (17). Different imaging techniques and in silico models have been devised to predict or monitor biodistribution as well as quantitative structure-property relationship of liposomes (18) (19) (20) .
Almost 50 years after the discovery of liposomes, the US FDA has approved 13 liposomes based products for human use (Table 1) . In addition, a large number of liposomal products are in different phases of clinical trials (21,22). The next generation of liposomes are prepared conventionally either by modification of conventional preparation methods or special laboratory techniques. Liposomes are prepared by a lipid hydration, ethanol injection, freeze-thawing and reverse phase evaporation. In the lipid hydration method, lipid is dissolved in an organic solvent followed by drying to form a thin lipid film. This lipid film is hydrated using an aqueous solution of a drug and vortexed to form liposome system. In the ethanol injection method, lipid is dissolved in ethanol and its solution injected into an aqueous buffer containing the drug. In the freezethawing method, a lipid film is hydrated with an aqueous buffer solution and subjected to repeated cycles of freezing and thawing thus yielding a liposome system. In the reverse phase evaporation technique, a solution of a lipid and an organic solvent is added to an aqueous buffer solution to form a water in oil emulsion. This emulsion is subjected to evaporation under low pressure which results in the formation of a liposome system. Researchers have also designed in-house laboratory scale detection methods for the characterization and quality control of liposomes (23). However, the scale-up of these sophisticated laboratory methods to industrial production still needs to be addressed. Major issues in industrial manufacturing of liposomes include the presence of residual organic solvent, difficulty of controlling liposome size distribution and stability problems associated with sterilization processes (24).
ADVANCEMENT IN LIPOSOME TECHNOLOGY
In this section, attempts have been made to reviews the next generation of liposomes, their preparation methods and progress in clinical applications.
Archeosomes: Archeosomes are liposomes made up of polar lipids of archaebacteria. Archaebacteria are extremophiles which can live in extremes of environment. Their cell membrane consists of etherlipids which differs from other eukaryotic and prokaryotic membrane lipids. 
Ethosomes:
Ethosomes are transdermal liposomes containing hydroalcoholic core for enhanced penetration through the stratum corneum and other skin layers (Figure 4 ). (60, 61) .
Applications: Ethosomes serves as carriers for transcutaneous immunization (62) and gene delivery (63) . These are also employed for antiinflammatory (64, 65) , anti-psoriatic (66) and antimicrobial therapeutics (67) . Recent research has focused on binary ethosomes that contain polyols (such as propylene glycol) in addition to alcohol and water inside the ethosome core. Ethosomes and binary ethosomes have demonstrated superior penetration efficiency over conventional liposomes, transferosomes and other specialized drug delivery systems (68) (69) (70) (71) .
Exosomes:
Exosomes are phospholipid vesicles released by normal and tumor cells. In normal cells, they control cell-to-cell communication by paracrine signals to induce protein synthesis and alter the behavior and proliferation of surrounding cells. In tumor cells, they help in maintaining a tumor specific environment by paracrine signaling for promoting angiogenesis and lymphocyte apoptosis. These tumor derived exosomes have been isolated from patients and loaded with anticancer agents for individualized therapy of cancer. Their surface complexity and non-specificity hindered their use in drug delivery systems and trigger the development of exosome-mimetic, liposomes with functional components of exosomes (72) (73) (74) . The endogenous origin of exosomes is advantageous over synthetic nanocarriers due to excellent biocompatibility and targeting potential (75) . Preparation: Exosomes secreting cells are immortalized in vitro and exosomes are separated by differential centrifugation. Therapeutic agents are loaded into prepared exosomes by standard transfection techniques such as electroporation or lipofection. Electroporation is a physical method in which successive electric impulses are applied on exosomes which increase their permeability and entrapment of DNA molecules. Colloidal stability of exosomes after electroporation should be given keen consideration which is function of composition of media, exosomes concentration and charge applied (76) . Lipofection is a chemical techniques in which positively charged lipids bind negatively charged DNA molecules (77) .
Applications: Exosomes are employed for the delivery of genes because of their intrinsic ability to cross biological barriers and their non-immunogenic nature (78). Suppression of the immune system by cancerous exosomes has been assumed to treat autoimmune diseases (77) . Some researchers are thus focusing on targeted cancer vaccination and individualizing therapy with patient derived exosomes (79,80).
Gas containing liposomes:
These liposomes are modified to encapsulate a gas bubble that contains gas up to 80% of their inner capacity (81,82). Liposomes loaded with chemical agents such as ammonium chloride produce gas bubbles and cause the release of loaded therapeutic moiety (83). Targeted gas containing liposomes are currently being investigated for deep tissue tumor diagnosis (84) . Preparation: Gas containing liposomes are prepared by the film hydration and freeze thawing method. The process is carried out in the presence of gas to be encapsulated under high pressure (84) .
Applications: Targeted gaseous liposomes are employed for tumor tissue detection. These liposomes oscillate under low frequency ultrasound thereby producing a characteristic echo which is different from the echo of surrounding tissues (81). Therapeutic drug molecules loaded to gas containing liposomes release the drug at a controlled rate by applying specific ultrasound frequency outside the body region (82). Nitric oxide containing liposomes have been used to induce relaxation of the vascular smooth muscles (83). Xenon gas is reported to be an effective and nontoxic neuroprotectant agent when encapsulated in gaseous liposomes (85) .
Immunoliposomes:
Surface ligands such as monoclonal antibodies when attached to the liposomes are effectively targeted to different body tissues (86) . Immunoliposomes selectively bind to a receptor of target cell and become internalized, thereby increasingthe bioavailability of therapeutics. These Immunoliposomes confine the action of very toxic and/or potent pharmacological agents at target tissues and safeguard other body tissues from unnecessary exposure (86) (87) (88) . Development of the immunoliposomes in the 1980s provided a milestone in the evolution of advanced multifunctional liposomes ( Figure 5 ).
Preparation: Antibodies or antibody fragments are conjugated on liposome surface by mixing isolated antibody fragments with already prepared cationic liposomes. These immune-cationic liposomes are then mixed with therapeutic drug solution to form a drug-loaded immunoliposomes (89) . Recently, folate conjugated immunoliposomes have been prepared by one step microfluidic synthesis. In this method, folate conjugated phospholipid are passed through thermoplastic microfluidic device in a controlled laminar flow. This method can produce immunoliposomes in nano size range (90) .
Applications: Various monoclonal antibodies produced against different cancerous tissues have been used in cancer chemotherapy by formulating immunoliposomes. Multifunctional immuoliposomes have long circulation time and can carry more than one therapeutic and diagnostic agents (91) . Immunoliposomes have successfully been targeted to tumor cells (92) (93) (94) (95) , vascular endothelium (96) and infarcted heart tissue (97) . Immunoliposome are meant to improve safety profile of potent drugs by limiting drug exposure to target sites but recently reported results of Shmeeda et al., (2013) found that liposomal zoledronic acid was almost 50 times more toxic than free zoledronic acid solution. Toxicity was found to be dose dependent and attributed to unexpectedly high macrophages activation (98) . However, this enhanced toxicity might underlie entirely different mechanism because liposomal drugs, such as cisplatin, have been found to act differently than free drug at molecular level (99) . Current research is focused on developing bispecific ligands for dual targeting of tumor cells with more specificity (100). Moreover, liposomes displaying antigenic proteins and glycan ligands for the inhibitory co-receptor CD22 have been reported to elicit only antigen specific immune response and prevent B cell mediated harmful immune responses (101) . Harmful immune and inflammatory response to immunostimulatory agents can also be prevented by localized immunotherapy. One such strategy is the intratumoral injection of controlled size liposomes which allows dissemination of liposomal drugs into tumor tissue and tumor draining lymph nodes but prevents entry into systemic circulation due to large size of liposomes (102) .
Immunosomes and Virosomes:
Immunosomes are prepared by attaching viral glycoproteins on liposome lipid bilayer. Immunosomes are nano-sized globular particles having uniform glycoprotein attachments (50-60 nm) (103) (104) (105) . Immunosomes are non-toxic vaccine carriers with strong immuno-adjuvant properties to stimulate or inhibit the humoral as well as cell mediated immunity. Research on immunosomes has led to the discovery of virosomes. Virosomes are substituted viral coats of lipids, glycoproteins, haemagglutinin and other antigenic components. Virosomes lack viral nucleic material and fail to replicate (106) . Immunosomes differ from virosomes in their composition. Immunosomes are a type of liposomes that contain only certain isolated antigens of a virus while virosomes are complete virus shells with all viral lipids, glycoprotein and antigenic determinants ( Figure 6 ). Usually, these terms are used interchangeably but the term virosome is preferred over immunosome to avoid any confusion with immunoliposomes. The surface fastened viral glycoproteins provide an indistinguishable structure to immunosome and virosome and is responsible for their immunogenic properties similar to the parent virus (107 Application: Immunosomes and virsomes are vaccine carriers with strong adjuvant propertiesagainst AIDS, influenza, hepatitis and rabies viruses in mice. These carrier vaccines have also proved to be effective against these viral strains in ex-vivo and animal studies (110-114). The vaccines Epaxal (Hepatitis A) and Inflexal (Influenza) are already available for clinical use (Table 1) .
Immune stimulating complexes (ISCOMs)
ISCOMs are vaccine adjuvants which induce a wide range of antibodies by humoral activation as well as strong cell mediated responses against antigen. Major structural components of ISCOMs are cholesterol, phospholipids and quiallaja saponins (Quil A). They contain amphiphilic antigens like membrane proteins and in aqueous solution can be stored for years at cool temperature (115).
Preparation: ISCOMs are prepared by ether injection method. Phospholipids and cholesterol are dissolved in ether and injected into aqueous solution containing Quil A. An optimal ratio (5:3:2) of Phospholipids, Quil A and cholesterol and injection rate ensures homogenous preparation (116).
Applications:
Immune stimulating complexes produce a wide range of antibodies by humoral and cell mediated responses making them a carrier of choice for vaccines against intracellular and chronic infections (117) . Posintro 
Lipoplexes
Lipoplexes are formed when cationic lipids are coupled with a negatively charge of DNA molecules. Lipoplexes are considered toxic due to the presence of cationic lipids. Toxicity can be reduced by using compact plasmid DNA (pDNA). When an elongated DNA is transformed into a compact form, its overall negative charge decreases and lesser amount of cationic lipid is needed (119) (120) (121) (122) . Effective lipoplex formulations require optimization of size and structure of the selfassembled vesicles (123) . Major disadvantage of lipoplexes is acute inflammatory response after administration. The sequential administration of plasmid DNA and lipoplexes as repeated doses has been found to minimize the acute inflammation and other lipoplexes associated toxicities (124) .
Preparation: pDNA is isolated from purified plasmid using suitable techniques. Cationic liposomes are prepared by lipid hydration and sonicated until a clear translucent solution is formed. The pDNA solution is added to cationic liposomes and mixed gently. The obtained lipoplexes suspensions is stored at room temperature for 15-30 min before use (125) .
Applications: Lipoplexes are used for viral DNA transfection avoiding virus associated immunogenicity and oncogenecity. Lipoplexes are easier to produce compared to other viral carrier preparations (126) (127) . Incorporation of co-lipids such as dioleyl phosphatidylethanolamine (DOPE), cholesterol and some fatty acids have been reported to increase gene transfection rates. Co-lipids make lipoplexes more rigid and increase their size which facilitates their fusion with cell membranes and phagocytosis. Lipoplexes may also act as immuneadjuvant when admixed with protein antigens. However, their adjuvant activity is primarily due to enhanced uptake of proteins by antigen presenting cells as compared to negatively charged liposomes that promote activation and maturation of antigen presenting cells (128) . Recent research has focused on making lipoplexes more plasma friendly, optimizing morphological features which can control cellular uptake and intracellular disposition (129) (130) . The manipulation of co-lipids has led to improved transfection efficiency (131) (132) and targeted delivery (133) .
Magnetic liposomes:
These are the type of advanced liposomes which contain magnetic or paramagnetic entities such as gadolinium (Gd (Figure 9 ). Magnetic liposomes also act as a contrast agent in MRI imaging (136) .
Preparation: Magnetic liposomes are prepared by a lipid hydration method. In this method, the lipid is dissolved in an organic solvent and dried to form a thin lipid film. A magnetizing agent is dissolved in water to form an aqueous magnetizing solution. The thin layer of lipid in the round bottom flask is hydrated with the aqueous magnetizing solution to form magnetic liposomes (137) .
Applications:
Magnetic liposomes provide "clickable" release of therapeutic agents by applying an alternating magnetic field. Magnetic liposomes provide permeability and controllable release (138) (139) . Magnetic liposomes are decorated with various surface ligands, such as polyethylene glycol, as targeting ligands (140) , and are bi-functional which means they can carry fluorescent probe and MRI contrast agents for imaging as well as functional DNA delivery to the same cell (141) . Recent research has reported super magnetic liposomes to treat cancer tissues and their metastasis without involving surgery or chemotherapeutic agents (142) . When targeted super magnetic liposomes are subjected to an alternating magnetic field, they produce local hypothermia (about 45 o C) and cause tumor tissue necrosis (143) .
Niosomes:
Niosomes are unilamellar or multilamellar vesicles composed of non-ionic surfactants (Figure 10 (144) (145) (146) (147) .
Preparation: Niosomes can be prepared by conventional lipid hydration and ether injection method with slight modifications depending on noisome application. Size homogeneity can be achieved by using an extrusion method (148-150).
Application: Niosome have been used for the treatment of leishmaniasis (151), cancer therapy (152,153), immune induction (154) and as carrier for diagnostic agents (155) . Research has been focused on providing controlled release of antimicrobial agents, anti-inflammatory drugs, peptides and various macromolecules (156) (157) (158) (159) (160) . Cationic niosomes have been prepared by the combination of cationic lipids and non-ionic surfactants in niosomes (161) . Recently, novel multicomponent drug delivery systems have been prepared in which preformed niosomes were loaded into liquid crystal gel. Both components of this system were prepared from the same mixture anionic and non-ionic surfactant for enhanced drug permeation after topical application (162) .
pH sensitive liposomes:
In viral infections, mild acidic conditions are responsible for fusion of virus envelopes with cell membranes. This observation led to the development of pH sensitive liposomes which release loaded therapeutics at acidic pH. Serum albumin and protein fragments have been reported to enhance liposome fusion at a lower pH of 6.5 (163) (164) (165) (166) . However, pH sensitive liposomes provide bioresponsive delivery to tissues. Lower pH values destabilize the lipid bilayer and drug is released at tumors, infections and inflammation (167) (168) (169) . (Figure 9 ). Phosphatidylethanolamines and a stabilizing amphiphiles are used to stabilize liposomes at acidic pH (170) (171) (172) . During endocytosis, the pH sensitive liposomes are exposed to the acidic environment of endosomes and may release their content inside the cells.
Preparation:
Freeze thawing and reverse phase evaporation methods are used for the preparation of pH sensitive liposomes. Lipids, co-lipids and PEGare dissolved in an organic solvent. In freeze thawing, the lipid suspension is frozen followed by thawing in a water bath. After ten freeze-thawing cycles, pH sensitive liposomes are formed (173) . In the Reverse Phase Evaporation method, a lipid film is hydrated with another organic solvent followed by adding an aqueous saline solution of therapeutics. The emulsion is vortexed and the organic solvent is evaporated to form pH sensitive liposomes (174) .
Applications: pH sensitive fusogenic polymers have been subject of extensive research for the development of pH sensitive liposomes (175, 176) . Hydrophobic derivatives of natural polymers have been conjugated with phospholipids molecules. Such liposomes demonstrate excellent pH responsiveness in vitro and in vivo (177, 178) . Recent advancements have led to the development of 'fliposomes' which are more stable and show instant release in seconds (179) . Fliposomes contain flipids, the lipids that undergo conformational switch at lower pH and destabilize the liposome bilayer (180) . They are used for delivery of gemcitabine (169) and cisplastin (181) . Research has been focused on the development of stealth and targeted pH sensitive liposomes (182) . In addition, understanding the polymer backbone structure and resulting hydrophobic behavior can provide very helpful insights into membrane interactions and fusogenic activity of these liposomes (183, 184) . Juan et al (2012) have reported a pH sensitive liposome using NH 4 -HCO 3 for the release of doxorubicin. Within the target cell, CO 2 is liberated from NH 4 -HCO 3 which lowers pH and enhance drug release (185) .
Polymerized liposomes:
Leakages of therapeutics from the conventional liposomes which are toxic to the normal tissues poses a serious challenge to clinical applications. This problem can be solved by polymerization of the lipids in the liposome bilayer. These polymerized liposomes are completely stable, provide modified release and enhance the half-life of therapeutic agents (186) (187) (188) . Polymerized liposomes should be differentiated from capsosomes. Capsosomes are not true liposomes but contain a polymeric capsule with multiple subcompartments composed of liposomes (Figure 7) , (189) . Preparation: Polymerized liposomes are prepared by film hydration method. Cholesterol is chemically combined with polymerizable monomer. Phospholipids and the monomeric cholesterol are mixed in chloroform and dried in a rotary evaporator to form a thin film. The lipid film is hydrated with an aqueous buffer and sonicated for 30 minutes resulting in liposome formation. Polymerization of the lipid bilayer may be carried out by thermal, radiation or redox reaction. In thermal polymerization, the liposomes are heated to 60-70 0 C in the presence of free radical donor such as Azobis-isobutyronitde which initiates a polymerization reaction (190) . In the radiation polymerization, liposomes are subjected to ultra violet (UV) radiations for 1-2 hours resulting in lipid polymerization (187) . In the redox polymerization, redox initiator system consisting of ammonium per-sulphate and sodium meta-bisulphite are added to liposome formulations and heated in the presence of N 2 to initiate polymerization. Residual polymeric monomers, reactants and un-entrapped drug are removed by dialysis (191) .
Applications: Polymerized liposomes can be used for parenteral, oral and mucosal delivery of various diagnostic (191) (192) (193) and therapeutic agents. These are employed as vaccines and for the delivery of allergens, carbohydrates and antimicrobial agents (194) (195) (196) . Polymerized liposomes are prepared in nanometer size range with multifunctional variants for controllable release responsive to pH and magnetic fields (197) (198) (199) (200) . In a recent study, liposomes were functionalized with surface adsorption of chitosan followed by polymerization of lipid bilayer.
Proliposomes:
Proliposomes are dry and free flowing particles consisting of phospholipids coatings on water soluble powder particles. These lipid particles yield homogenous suspension of liposomes when dissolved in an aqueous solution. Proliposomes solve the problem associated with sterilization of liposomes as they have a high storage stability and provide simple large-scale production (201) (202) (203) . Recently, liquid proliposomes have been reported that spontaneously form liposomes upon hydration (204) The resulting proliposomes can be lyophilized or desiccated overnight to yield a fine free flowing powder (205) . Proliposomes can also be prepared by fluid bed coating, spray drying and freezethawing depending upon the type of drug and its application (206) .
Liquid proliposomes were prepared by dissolving hydrophobic drug, phospholipid, sodium deoxycholate, poloxamer and polyethylene glycol in ethanol. This light yellowish liquid was filled in hard gelatin capsule and dried. These liquid proliposomes will yield liposomes when manually mixed with distilled water (204) . 
Applications:
The administration of dry proliposomes via inhalation provide enhanced bioavailability and sustained therapeutic effects (207, 208) . Proliposomes are reconstituted into a prescribed solvent to yield a liposome system. Effervescent proliposomes provide carbon dioxide upon dissolution (209) . Proliposomes show great flexibility in the route of administration including reconstituted parenteral, oral, topical, intranasal administration and as dry powder aerosol (210) . Proliposomes have successfully been used for enhancing bioavailability of anticancer drugs and other therapeutic agents (211) (212) (213) .
Temperature sensitive liposomes:
Temperature sensitive lipids are stable at body temperature and undergo phase transition from gel to liquid at higher temperatures and provide a successful mean for targeted delivery (214) . Temperature sensitive liposomes circulate throughout the body but when they reach an area of significant hyperthermia, they release therapeutics due to increased fluidity of the lipid bilayer ( Figure  9 ).
Preparation:
Temperature sensitive liposomes are prepared with slight modifications of the reverse phase evaporation and lipid hydration method. In both methods, temperature sensitive lipids are mixed in an organic solvent followed by evaporation of the solvent in a rotary evaporator. In the hand shake method, the lipid film is hydrated with an aqueous solution containing a therapeutic agent and a surfactants. The system is heated above their phase transition temperature to yield temperature sensitive liposomes (215) . In the reverse evaporation method, the lipid film is redissolved in an organic solvent followed by the addition of an aqueous saline solution containing the therapeutic moiety. The mixture is heated to (221) to control the release of therapeutic agents maintaining mild external hyperthermia generated by focused ultrasound (222) , radiofrequency waves (223) and alternating magnetic field (224, 225) . Recently, two steps hyperthermia has been reported to enhance antitumor activity of the encapsulated drugs. First hyperthermia (41°C) induced hyperpermeable tumor vasculature which persisted for 8 hours while second hyperthermia (42°C or above) induced drug release from temperature sensitive liposomes (226) .
Transferosomes:
These are ultra-deformable and stable advance liposomes which can cross the pores of the stratum corneum. The degree of deformability of transferosomes is directly related to their bioavailability. Transferosomes are prepared from different ratios of phosphatidylcholine and surfactants. Surfactants act as edge-activators and incorporate deformability into transferosomes ( Figure 10) . By changing the type and ratio of surfactant, one can optimize the vesicle morphology, size and therapeutic loading (227, 228) . The addition of permeation enhancers into transferosomes further improves therapeutic delivery through the skin (229).
Preparation:
Transferosomes are prepared by a film hydration method. Lipids and surfactants are dissolved in an organic solvent. The organic solvent is evaporated using a rotary evaporator to form a lipid film. This film is hydrated with an aqueous buffer and sonicated for 5 minutes to obtain transferosomes (230) .
Applications:
Transferosomes have been used to deliver macromolecules which are difficult to be transported by other dosage forms. Transulin is transferosomal insulin complex which shows in vivo delivery similar to subcutaneous insulin and lacks the problem associated with non-compliance of injections (231) . Recent research has shown that corticosteroids might be ideal candidate for transferosomal delivery (232) (233) (234) .
Different types of next generation liposomes or their combination present exciting solutions for diagnostic as well as therapeutic applications. Table  2 summarizes challenging disease conditions that have been broadly investigated with liposomes based therapy. 
